Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: betamethasone dipropionate; calcipotriene hydrate

« Back to Dashboard

Betamethasone dipropionate; calcipotriene hydrate is the generic ingredient in two branded drugs marketed by Tolmar and Leo Pharma As, and is included in three NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are sixty-five drug master file entries for betamethasone dipropionate; calcipotriene hydrate. Four suppliers are listed for this compound.

Summary for Generic Name: betamethasone dipropionate; calcipotriene hydrate

Tradenames:2
Patents:4
Applicants:2
NDAs:3
Drug Master File Entries: see list65
Suppliers: see list4

Pharmacology for Ingredient: betamethasone dipropionate; calcipotriene hydrate

Clinical Trials for: betamethasone dipropionate; calcipotriene hydrate

The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris
Status: Completed Condition: Psoriasis Vulgaris

A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
Status: Completed Condition: Psoriasis

LEO 90105 Ointment in Japanese Subjects With Psoriasis
Status: Completed Condition: Psoriasis

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
Status: Recruiting Condition: Psoriasis Vulgaris (Plaque Psoriasis)

Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis
Status: Completed Condition: Scalp Psoriasis

Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
Status: Not yet recruiting Condition: Psoriasis Vulgaris

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris
Status: Completed Condition: Psoriasis Vulgaris

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185May 9, 2008RXYes6,753,013<disabled>Y<disabled>
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185May 9, 2008RXYes6,787,529<disabled>Y<disabled>
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852Jan 9, 2006RXYesRE39706<disabled>YY<disabled>
Tolmar
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL201615Jan 14, 2013RXNo<disabled><disabled>
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852Jan 9, 2006RXYes6,753,013<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc